WNT5A and rheumatoid arthritis: Wnt5a promotes the expression of inflammatory cytokines in synovial tissue [77], induces chemokine production [78], and regulates MMP production [79], and therefore, is implicated in bone and cartilage degradation and is a promising therapeutic target for rheumatoid arthritis.